ClinicalTrials.gg
CompletedNCT07462312Updated Oct 2, 2026

MentalGym™ and NeuroBrave™ Guided Wearable-Assisted Physiology Regulation Training for PTSD (PRTP)

An interventional study of Mental Gym® Biofeedback System in PTSD - Post Traumatic Stress Disorder, sponsored by NeuroBrave ltd.. Completed at 1 site in Israel. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by NeuroBrave ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2025, registered Mar 2026).
Updated Oct 2, 2026Now CompletedEligibility revised+3 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This randomized controlled trial (RCT) will evaluate the effectiveness of a digital biofeedback-based intervention ("Mental Gym®") designed to reduce Posttraumatic Stress Disorder (PTSD) symptoms and improve mental health. The intervention combines daily HRV biofeedback exercises using a wearable device (Garmin watch), a dedicated mobile application, and weekly group guidance sessions. A delayed-intervention control group design will be used. To account for expected attrition and ensure a final sample of 60 participants, approximately 80 subjects will be recruited. Physiological and self-report data will be collected pre- and post-intervention, weekly during the intervention, and at follow-ups (3 months post-intervention). The study population consists of combat veterans diagnosed with PTSD.

02

Conditions studied

  • PTSD - Post Traumatic Stress Disorder

Browse trials for

03

In context

Combat Disorders

200 studies on the registry are indexed under Combat Disorders; 90 are open to participants now.

This study's enrollment of 80 is above the median of 72 across 167 interventional studies indexed under Combat Disorders.

Browse Combat Disorders studies →

Lead sponsor

This is the only study on the registry with NeuroBrave ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sex: Male.
  • Age: 18 to 50 Years.
  • Diagnosis: Clinical diagnosis of Posttraumatic Stress Disorder (PTSD) with mild to moderate-severe symptom intensity.
  • Symptom Severity: A PCL-5 total score of up to 60 at screening.
  • Traumatic Event: PTSD diagnosis based on a traumatic event that occurred in the year 2000 or later.
  • Service Eligibility: Eligibility for Ministry of Defense (MOD) rehabilitation services.
  • Technical Proficiency: Ability to use a smartphone and a wearable device.

Exclusion criteria

Exclusion Criteria:

  • High Symptom Severity: PTSD symptom severity exceeding the moderate-severe range (PCL-5 score > 60) or requiring more intensive clinical intervention.
  • Psychiatric Stability: Acute psychiatric instability, including active suicidal ideation or psychosis.
  • Medication: Current use of Olanzapine (Zyprexa) or Quetiapine (Seroquel).
  • Sleep Disturbances: Severe sleep impairment (score > 7 on the The Insomnia Severity Index).
  • Functional Impairment: Severe impairment in concentration or cognitive processing that precludes the use of digital biofeedback tools.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Mental Gym® Immediate Intervention

    Behavioral: Mental Gym® Biofeedback System

  • No intervention
    Delayed Intervention (Waitlist Control plus Garmin Watch)

    Participants in this arm will initially serve as a no-intervention control group for a period of 8 weeks, during which they will continue with their Treatment as Usual (TAU). Following this 8-week period, they will receive the full 'Mental Gym®' intervention, identical to the experimental group, including the mobile application, and weekly sessions.

Interventions

  • BehavioralMental Gym® Biofeedback System

    The intervention is an 8-week hybrid program designed to reduce symptoms of PTSD and improve mental health. The program includes weekly online sessions (via Zoom) with a specialist psychologist experienced in biofeedback and trauma therapy. These sessions guide participants through the program, provide education on trauma and autonomic system and explain the biofeedback exercises. In addition to the weekly group sessions, participants engage in a dailyself-practice delivered through the NeuroBrave Sense mobile application, utilizing the provided wearable device ( Garmin watch) for real time biofeedback practices. Supplementary mental practice assignments are also delivered to participants via WhatsApp.

06

What researchers measure

Primary outcomes

  1. Change in PTSD Symptom Severity (PCL-5 Total Score)

    The primary outcome is the change in the total score of the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5). The PCL-5 is a 20-item self-report measure; items are rated on a 0-4 point scale. Total score ranges from 0 to 80, where higher scores indicate greater symptom severity. PCL scores are expected to reduce in the intervention but not in the control groups.

    Time frame: Baseline (Week 0) and Post-Intervention (Week 8).

Secondary outcomes

  1. Long term retention of Treatment Effects in the Intervention Group

    To assess long term improvement trajectories and retention, we will combine all intervention arm participants and conduct longitudinal within subjects analysis on primary and secondary change measures at post intervention, as well as 1.5-month Follow-up (Week 14), and 3-month Follow-up (Week 20). This analysis will also be used to identify subpopulations within our sample for whom the treatment was more or less beneficial. We expect the clinical improvement to remain significant through the follow up time points.

    Time frame: Baseline (Week 0), Post-Intervention (Week 8), 1.5-month Follow-up (Week 14), and 3-month Follow-up (Week 20)

  2. Change in Autonomic Regulation (Resting HRV)

    change in resting heart rate variability (HRV) will be used as a physiological marker of autonomic regulation. HRV will be derived from inter-beat interval data collected during 5 min resting conditions during the first and the last group sessions using a wearable device and summarised using standard time-domain metrics (e.g., RMSSD). Higher HRV values and lower heart rate (HR) reflect greater parasympathetic activity and improved autonomic regulation. Resting HRV scores are expected to increase and resting HR to decrease in the intervention but not in the control groups.

    Time frame: Baseline (Week 0) and Post-Intervention (Week 8)

  3. Change in Generalized Anxiety Symptoms (GAD-7)

    Generalized anxiety symptoms will be assessed using the Generalized Anxiety Disorder 7-item questionnaire (GAD-7), a validated self-report measure of anxiety severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptoms. Generalized anxiety symptoms are expected to reduce in the intervention but not in the control groups.

    Time frame: Baseline (Week 0) and Post-Intervention (Week 8)

  4. Change in Depressive Symptoms (PHQ-9)

    Depressive symptoms will be measured using the Patient Health Questionnaire-9 (PHQ-9), a validated self-report instrument assessing the severity of depressive symptoms over the past two weeks. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Depressive symptoms are expected to reduce in the intervention but not in the control groups

    Time frame: Baseline (Week 0), Post-Intervention (Week 8)

  5. Change in Psychological Resilience (CD-RISC-10)

    Psychological resilience will be assessed using the 10-item Connor-Davidson Resilience Scale (CD-RISC-10), a validated self-report measure of perceived resilience and stress coping capacity. Total scores range from 0 to 40, with higher scores indicating greater resilience.Psychological resilience is expected to reduce in the intervention but not in the control groups.

    Time frame: Baseline (Week 0), Post-Intervention (Week 8)

  6. Change in Sleep Quality (ISI)

    Sleep quality will be measured using the Insomnia Severity Index (ISI), a validated self-report questionnaire assessing subjective sleep quality. The total SQS score will be used, with higher scores indicating poorer sleep quality. Sleep quality is expected to reduce in the intervention but not in the control groups.

    Time frame: Baseline (Week 0), Post-Intervention (Week 8)

Other outcomes

  1. Weekly Change in PTSD Symptom Severity (PCL-6)

    The PTSD Checklist - 6-item version (PCL-6) is a validated self-report screening tool for Post-Traumatic Stress Disorder. It assesses symptoms such as intrusive thoughts, avoidance, and hyperarousal. Total scores range from 6 to 30, with higher scores indicate greater symptom severity. A decrease in scores over time represents clinical improvement.

    Time frame: Baseline, and weekly through Week 8

  2. Weekly Change in Psychological Wellbeing (ORS)

    The Outcome Rating Scale (ORS) is a 4-item visual analogue scale designed to measure change in three areas of client functioning: individual (personal well-being), interpersonal (family/close relationships), and social (work/school/friendships), as well as overall well-being. Total scores range from 0 to 40, with higher scores indicate better psychological wellbeing and functioning. An increase in scores over time represents improvement.

    Time frame: Baseline, and weekly through Week 8

07

Study locations

1 site
  • NeuroBrave LTD - Remote Site
    Jerusalem, Israel
08

References and documents

Publications

  • Cuyler RN, Katdare R, Thomas S, Telch MJ. Real-world outcomes of an innovative digital therapeutic for treatment of panic disorder and PTSD: A 1,500 patient effectiveness study. Front Digit Health. 2022 Nov 17;4:976001. doi: 10.3389/fdgth.2022.976001. eCollection 2022. PubMed 36465089 ↗
  • Schuman DL, Lawrence KA, Boggero I, Naegele P, Ginsberg JP, Casto A, Moser DK. A Pilot Study of a Three-Session Heart Rate Variability Biofeedback Intervention for Veterans with Posttraumatic Stress Disorder. Appl Psychophysiol Biofeedback. 2023 Mar;48(1):51-65. doi: 10.1007/s10484-022-09565-z. Epub 2022 Nov 4. PubMed 36331685 ↗
  • Tan G, Dao TK, Farmer L, Sutherland RJ, Gevirtz R. Heart rate variability (HRV) and posttraumatic stress disorder (PTSD): a pilot study. Appl Psychophysiol Biofeedback. 2011 Mar;36(1):27-35. doi: 10.1007/s10484-010-9141-y. PubMed 20680439 ↗
  • Rosaura Polak A, Witteveen AB, Denys D, Olff M. Breathing biofeedback as an adjunct to exposure in cognitive behavioral therapy hastens the reduction of PTSD symptoms: a pilot study. Appl Psychophysiol Biofeedback. 2015 Mar;40(1):25-31. doi: 10.1007/s10484-015-9268-y. PubMed 25750106 ↗
  • Morin CM, Belleville G, Belanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011 May 1;34(5):601-8. doi: 10.1093/sleep/34.5.601. PubMed 21532953 ↗
  • Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. J Trauma Stress. 2015 Dec;28(6):489-98. doi: 10.1002/jts.22059. Epub 2015 Nov 25. PubMed 26606250 ↗
  • Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. PubMed 11556941 ↗
  • Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18(2):76-82. doi: 10.1002/da.10113. PubMed 12964174 ↗
  • Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. PubMed 16717171 ↗
  • Lang AJ, Stein MB. An abbreviated PTSD checklist for use as a screening instrument in primary care. Behav Res Ther. 2005 May;43(5):585-94. doi: 10.1016/j.brat.2004.04.005. PubMed 15865914 ↗

Individual participant data

Plan to share: No

09

Updates

2 registry updates since Sep 25, 2026
Status
Recruiting→Completed
changed Sep 29, 2026
Primary completion
Sep 30, 2026→Sep 14, 2026 (actual)
Sep 29, 2026
Study completion
Sep 30, 2026→Sep 14, 2026 (actual)
Sep 29, 2026
Eligibility
Sex ALL→MALE; 2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Sex: AllNow Sex: Male.
  • EditedAge: 18 to 50 Years and older.
across 2 updates, Sep 29, 2026 – Oct 2, 2026
Show all 2 updates
  1. Oct 2, 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Sex: AllNow Sex: Male.
    • EditedAge: 18 to 50 Years and older.
  2. Sep 29, 2026
    Recruiting→Completed
    Primary completion Sep 30, 2026→Sep 14, 2026 (now actual)
    Study completion Sep 30, 2026→Sep 14, 2026 (now actual)
    Eligibility Sex ALL→MALE
    + 2 other changes: site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07462312
Lead sponsor
NeuroBrave ltd.
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Sep 15, 2025
Primary completion
Sep 14, 2026
Completion
Sep 14, 2026
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion